271 related articles for article (PubMed ID: 20405927)
21. Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008.
Michino M; Abola E; ; Brooks CL; Dixon JS; Moult J; Stevens RC
Nat Rev Drug Discov; 2009 Jun; 8(6):455-63. PubMed ID: 19461661
[TBL] [Abstract][Full Text] [Related]
22. Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson's Disease.
Jaiteh M; Zeifman A; Saarinen M; Svenningsson P; Bréa J; Loza MI; Carlsson J
J Med Chem; 2018 Jun; 61(12):5269-5278. PubMed ID: 29792714
[TBL] [Abstract][Full Text] [Related]
23. A Taxicab geometry quantification system to evaluate the performance of in silico methods: a case study on adenosine receptors ligands.
Kuder KJ; Michalik I; Kieć-Kononowicz K; Kolb P
J Comput Aided Mol Des; 2020 Jun; 34(6):697-707. PubMed ID: 32112287
[TBL] [Abstract][Full Text] [Related]
24. Recent Advances in the In-silico Structure-based and Ligand-based Approaches for the Design and Discovery of Agonists and Antagonists of A2A Adenosine Receptor.
Agrawal N; Chandrasekaran B; Al-Aboudi A
Curr Pharm Des; 2019; 25(7):774-782. PubMed ID: 30848185
[TBL] [Abstract][Full Text] [Related]
25. Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study.
Ciancetta A; Cuzzolin A; Moro S
J Chem Inf Model; 2014 Aug; 54(8):2243-54. PubMed ID: 25046649
[TBL] [Abstract][Full Text] [Related]
26. Integrating Pharmacophore into Membrane Molecular Dynamics Simulations to Improve Homology Modeling of G Protein-coupled Receptors with Ligand Selectivity: A2A Adenosine Receptor as an Example.
Zeng L; Guan M; Jin H; Liu Z; Zhang L
Chem Biol Drug Des; 2015 Dec; 86(6):1438-50. PubMed ID: 26072970
[TBL] [Abstract][Full Text] [Related]
27. Structurally Enabled Discovery of Adenosine A
Jazayeri A; Andrews SP; Marshall FH
Chem Rev; 2017 Jan; 117(1):21-37. PubMed ID: 27333206
[TBL] [Abstract][Full Text] [Related]
28. Pharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists.
Mustyala KK; Chitturi AR; Naikal James PS; Vuruputuri U
J Recept Signal Transduct Res; 2012 Apr; 32(2):102-13. PubMed ID: 22384789
[TBL] [Abstract][Full Text] [Related]
29. A2A receptor ligands: past, present and future trends.
Clementina M; Giuseppe S
Curr Top Med Chem; 2010; 10(9):902-22. PubMed ID: 20370660
[TBL] [Abstract][Full Text] [Related]
30. Novel approaches for targeting the adenosine A2A receptor.
Yuan G; Gedeon NG; Jankins TC; Jones GB
Expert Opin Drug Discov; 2015 Jan; 10(1):63-80. PubMed ID: 25311639
[TBL] [Abstract][Full Text] [Related]
31. Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson's Disease Dual Target Ligands.
Perez-Castillo Y; Helguera AM; Cordeiro MNDS; Tejera E; Paz-Y-Mino C; Sanchez-Rodriguez A; Borges F; Cruz-Monteagudo M
Curr Neuropharmacol; 2017 Nov; 15(8):1107-1116. PubMed ID: 28067172
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological relationships and ligand discovery of G protein-coupled receptors revealed by simultaneous ligand and receptor clustering.
Zhang C; Shao YM; Ma X; Cheong SL; Qin C; Tao L; Zhang P; Chen S; Zeng X; Liu H; Pastorin G; Jiang Y; Chen YZ
J Mol Graph Model; 2017 Sep; 76():136-142. PubMed ID: 28728042
[TBL] [Abstract][Full Text] [Related]
33. Reconstruction of apo A2A receptor activation pathways reveal ligand-competent intermediates and state-dependent cholesterol hotspots.
Lovera S; Cuzzolin A; Kelm S; De Fabritiis G; Sands ZA
Sci Rep; 2019 Oct; 9(1):14199. PubMed ID: 31578448
[TBL] [Abstract][Full Text] [Related]
34. Affinity Mass Spectrometry-Based Fragment Screening Identified a New Negative Allosteric Modulator of the Adenosine A
Lu Y; Liu H; Yang D; Zhong L; Xin Y; Zhao S; Wang MW; Zhou Q; Shui W
ACS Chem Biol; 2021 Jun; 16(6):991-1002. PubMed ID: 34048655
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure.
Ivanov AA; Barak D; Jacobson KA
J Med Chem; 2009 May; 52(10):3284-92. PubMed ID: 19402631
[TBL] [Abstract][Full Text] [Related]
36. Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space.
Jörg M; Shonberg J; Mak FS; Miller ND; Yuriev E; Scammells PJ; Capuano B
Bioorg Med Chem Lett; 2013 Jun; 23(11):3427-33. PubMed ID: 23602401
[TBL] [Abstract][Full Text] [Related]
37. Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A
Rucktooa P; Cheng RKY; Segala E; Geng T; Errey JC; Brown GA; Cooke RM; Marshall FH; Doré AS
Sci Rep; 2018 Jan; 8(1):41. PubMed ID: 29311713
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands.
El-Tayeb A; Gollos S
Bioorg Med Chem; 2013 Jan; 21(2):436-47. PubMed ID: 23245803
[TBL] [Abstract][Full Text] [Related]
39. Mass spectrometry-based ligand binding assays on adenosine A1 and A2A receptors.
Massink A; Holzheimer M; Hölscher A; Louvel J; Guo D; Spijksma G; Hankemeier T; IJzerman AP
Purinergic Signal; 2015 Dec; 11(4):581-94. PubMed ID: 26482925
[TBL] [Abstract][Full Text] [Related]
40. Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design.
Ciancetta A; Jacobson KA
Methods Mol Biol; 2018; 1705():45-72. PubMed ID: 29188558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
